Digital health company iLoF, developer of Optomics, an AI-powered photonics platform for developing personalised solutions for drug development and clinical research, announced on Wednesday a strategic collaboration with Bluepharma, a pharmaceutical company specialising in the research, development, and manufacturing of innovative healthcare products.

The partnership will integrate Optomics across the pharmaceutical value chain and enable the parties to explore, evaluate, and develop joint opportunities spanning drug development, R&D, and manufacturing.

For iLoF, this initiative further validates Optomics as a technological differentiator that provides rapid, high-precision insights to inform and accelerate drug development and therapeutic discovery.

Under the agreement, Optomics will be deployed in real-world settings, supporting the platform's evaluation against robust regulatory and quality standards across the pharmaceutical value chain.